Lee Ben H, Stoll Barbara J, McDonald Scott A, Higgins Rosemary D
Division of Neonatal-Perinatal Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Pediatrics. 2008 Feb;121(2):289-96. doi: 10.1542/peds.2007-1103.
We compared the development of adverse neurodevelopmental outcomes at corrected ages of 18 to 22 months for extremely low birth weight infants exposed prenatally to dexamethasone, betamethasone, or no steroid.
Study infants were extremely low birth weight (401-1000 g) infants who were in the care of National Institute of Child Health and Human Development Neonatal Research Network centers between January 1, 2002, and April 30, 2003; they were assessed neurodevelopmentally at corrected ages of 18 to 22 months. Outcomes were defined as Bayley Scales of Infant Development-II Mental Development Index of < 70, Bayley Scales of Infant Development-II Psychomotor Development Index of < 70, bilateral blindness, bilateral hearing aid use, cerebral palsy, and neurodevelopmental impairment. Neurodevelopmental impairment was defined as > or = 1 of the aforementioned outcomes.
A total of 1124 infants met entry criteria. There were no statistically significant associations between prenatal dexamethasone exposure and any follow-up outcome, compared with no prenatal steroid exposure. Prenatal betamethasone exposure was associated with reduced risks of hearing impairment and neurodevelopmental impairment and with increased likelihood of unimpaired status, compared with no prenatal steroid exposure. Compared with betamethasone, dexamethasone was associated with a trend for increased risk of Psychomotor Development Index of < 70, increased risk of hearing impairment, and decreased likelihood of unimpaired status.
Prenatal betamethasone exposure was associated with increased likelihood of unimpaired neurodevelopmental status and reduced risk of hearing impairment at corrected ages of 18 to 22 months among extremely low birth weight infants, compared with prenatal dexamethasone exposure or no prenatal steroid exposure. Pending a randomized, clinical trial, it may be in the best interests of infants to receive betamethasone, rather than dexamethasone, when possible.
我们比较了产前暴露于地塞米松、倍他米松或未使用类固醇的极低出生体重儿在18至22个月校正年龄时不良神经发育结局的发生情况。
研究对象为2002年1月1日至2003年4月30日期间在美国国立儿童健康与人类发展研究所新生儿研究网络中心接受治疗的极低出生体重儿(401 - 1000克);在18至22个月校正年龄时对他们进行神经发育评估。结局定义为贝利婴幼儿发育量表第二版心理发展指数<70、贝利婴幼儿发育量表第二版精细运动发展指数<70、双眼失明、双侧使用助听器、脑瘫以及神经发育障碍。神经发育障碍定义为上述结局中≥1项。
共有1124名婴儿符合纳入标准。与未产前暴露于类固醇相比,产前暴露于地塞米松与任何随访结局之间均无统计学显著关联。与未产前暴露于类固醇相比,产前暴露于倍他米松与听力障碍和神经发育障碍风险降低以及未受损状态可能性增加有关。与倍他米松相比,地塞米松与精细运动发展指数<70风险增加、听力障碍风险增加以及未受损状态可能性降低的趋势有关。
与产前暴露于地塞米松或未产前暴露于类固醇相比,产前暴露于倍他米松与极低出生体重儿在18至22个月校正年龄时神经发育状态未受损的可能性增加以及听力障碍风险降低有关。在进行随机临床试验之前,尽可能让婴儿接受倍他米松而非地塞米松可能最符合婴儿的利益。